FDA approves Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Media News)
Source: Roche Media News - March 19, 2019 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - March 19, 2019 Category: Pharmaceuticals Source Type: news

Dosing Adjuvant Chemo in Breast Cancer: Focus on Obesity Dosing Adjuvant Chemo in Breast Cancer: Focus on Obesity
Chemotherapy overdose may be avoided in obese patients with breast cancer using a tailored dosing strategy.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 18, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

EMA Starts Review on DPD Testing Before Chemotherapy EMA Starts Review on DPD Testing Before Chemotherapy
The European Medicines Agency (EMA) has launched a review into screening patients with cancer before they start certain chemotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 15, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Diabetes med may ease chemo side effects for breast cancer patients
A class of diabetes drugs that includes metformin could offer relief to some breast cancer patients from dangerous cardiovascular side effects of chemotherapy. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 14, 2019 Category: Consumer Health News Source Type: news

Study: Less-Invasive Mesothelioma Surgery Yields Better Results
A team of researchers at the Hyogo College of Medicine in Nishinomiya, Japan, studied the outcomes for pleural mesothelioma patients who received surgery at their facility between 2004 and 2016. The results: More aggressive surgery did not help mesothelioma patients live longer. “We showed that introducing less-invasive surgical techniques could decrease surgical risks without compromising survival,” the researchers wrote in their study, published in January in Seminars in Thoracic and Cardiovascular Surgery. “Surgery that is less invasive than conventional extrapleural pneumonectomy could achieve lower ...
Source: Asbestos and Mesothelioma News - March 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

'Molecular wiring of tumour' predicts breast cancer relapse
New research could lead the way to molecular based treatment and follow-up plans Related items fromOnMedica Thousands of women with breast cancer may be spared chemotherapy Benefit of Herceptin in more breast cancer cases MRI in breast cancer fails to cut reoperation rate Mortality higher if using paroxetine and tamoxifen Physical problems after breast cancer limit survival (Source: OnMedica Latest News)
Source: OnMedica Latest News - March 14, 2019 Category: UK Health Source Type: news

Ovarian cancer patient, 25, learns she can't have children due to emergency hysterectomy
Shaylee Bedward, 25, from Bloomington, Indiana, was diagnosed with stage 3 ovarian cancer in October 2017. After chemotherapy didn't work, she underwent a hysterectomy. (Source: the Mail online | Health)
Source: the Mail online | Health - March 13, 2019 Category: Consumer Health News Source Type: news

Stress hormones promote breast cancer metastasis
(University of Basel) Scientists from the University of Basel and the University Hospital of Basel have deciphered the molecular mechanisms linking breast cancer metastasis with increased stress hormones. In addition, they found that synthetic derivatives of stress hormones, which are frequently used as anti-inflammatory in cancer therapy, decrease the efficacy of chemotherapy. These results come from patient-derived models of breast cancer in mice and may have implications for the treatment of patients with breast cancer, as reported in Nature. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 13, 2019 Category: Biology Source Type: news

CBD Oil Is Everywhere, But Is It Really Safe and Healthy?
You might have seen it in your neighborhood health store, your local spa or your corner coffee shop. CBD, aka cannabidiol, is getting mixed into cocktails, lotions and drinks. But what is CBD, exactly? Does it have real health benefits? Is it even safe? To get a better understanding of the compound, TIME spoke to two scientists on the cutting edge of CBD research: Dr. Esther Blessing, an associate professor of psychiatry at New York University, and Margaret Haney, professor of neurobiology at Columbia University Medical Center and director of the university’s Marijuana Research Laboratory. Blessing and Haney agree th...
Source: TIME: Health - March 12, 2019 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized onetime Research Source Type: news

Mesothelioma Treatment Combines Proton and Photodynamic Therapy
Intraoperative photodynamic therapy combined with novel proton radiation improved survival time significantly for recent patients with advanced-stage pleural mesothelioma. The study — the first to measure the impact of this combination — involved 10 consecutive patients treated at the University of Pennsylvania’s Abramson Cancer Center. The treatment regimen resulted in a 90 percent, two-year disease control rate and an impressive 30.3-month median overall survival from the time of diagnosis. All 10 patients were diagnosed before treatment began with stage 3 or stage 4 disease, which typically results in ...
Source: Asbestos and Mesothelioma News - March 12, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Smart Biopsy Device Could Diagnose Breast Cancer Using Miniature Radiofrequency Sensors
Normally, when a physician notices a suspicious mass or lesion on a mammogram, he or she will request an ultrasound to explore it further. Based on those results, a biopsy may be performed to determine whether the mass is cancerous. “Unfortunately, right now, in some cases, physicians either overdiagnose or underdiagnose based on that biopsy, because with ultrasound they can only see so much,” said Lori Chmura, CEO of Dune Medical Devices. “The doctor is essentially going in blindly, trying to see what looks like the most suspicious area, and they’re t...
Source: MDDI - March 12, 2019 Category: Medical Devices Authors: Susan Shepard Tags: Business Source Type: news

Antioxidant-rich organic apple peels possess potent anti-cancer benefits
(Natural News) Cancer patients who do not want to follow the conventional treatment path – which usually includes surgery, chemotherapy, radiation or a combination of all three – have been known to embrace a variety of costly and sometimes even bizarre treatments to fight their disease. For those who have received a cancer diagnosis, the... (Source: NaturalNews.com)
Source: NaturalNews.com - March 12, 2019 Category: Consumer Health News Source Type: news

Adding docetaxel-based chemotherapy to standard treatment for high-risk prostate cancer
(NRG Oncology) Researchers theorized that adding adjuvant docetaxel, a cytotoxic chemotherapy drug, to the standard of care RT and long-term AS treatment could potentially improve overall survival and clinical outcomes for men with localized, high-risk prostate cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 12, 2019 Category: Cancer & Oncology Source Type: news

Targeting stem-like cells could prevent ovarian cancer recurrence
(University of Pittsburgh) A new drug takes out the 'seeds' that cause ovarian cancer to come back after chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 12, 2019 Category: Cancer & Oncology Source Type: news

FDA Approves 1st Immunotherapy Breast Cancer Drug
The combination of immunotherapy (Tecentriq) and chemotherapy (Abraxane) received accelerated approval for triple-negative breast cancer that is locally advanced or has spread, cannot be surgically removed, and has cells that have a protein called PD-L1, CNN reported. (Source: WebMD Health)
Source: WebMD Health - March 12, 2019 Category: Consumer Health News Source Type: news

FDA Approves First Immunotherapy Drug for Breast Cancer
MONDAY, March 11, 2019 -- The U.S. Food and Drug Administration has given its blessing to the first immunotherapy regimen for breast cancer. The combination of immunotherapy (Tecentriq) and chemotherapy (Abraxane) was given accelerated approval for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 11, 2019 Category: Pharmaceuticals Source Type: news

Association Between Diet and Chemotherapy-Induced Neuropathy Association Between Diet and Chemotherapy-Induced Neuropathy
Foods like citrus and grains may affect severity of peripheral neuropathy symptoms during taxane therapy for breast cancer.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 11, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

New breast cancer care 'may save 500 lives a year'
Most of the 2,000 UK patients diagnosed each year with stage four of the disease are given chemotherapy and anti-hormonal drugs. (Source: the Mail online | Health)
Source: the Mail online | Health - March 11, 2019 Category: Consumer Health News Source Type: news

Roche ’s VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane
Roche today announced US Food and Drug Administration approval of the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying triple-negative breast cancer (TNBC) patients eligible for treatment with the Roche cancer immunotherapy Tecentriq ®(atezolizumab) plus chemotherapy (Abraxane® [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]). (Source: Roche Investor Update)
Source: Roche Investor Update - March 11, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane
Roche today announced US Food and Drug Administration approval of the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying triple-negative breast cancer (TNBC) patients eligible for treatment with the Roche cancer immunotherapy Tecentriq ®(atezolizumab) plus chemotherapy (Abraxane® [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]). (Source: Roche Media News)
Source: Roche Media News - March 11, 2019 Category: Pharmaceuticals Source Type: news

FDA grants Roche ’s Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer
Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Tecentriq ® (atezolizumab) plus chemotherapy (Abraxane® [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in people whose tumours express PD-L1, as determined by an FDA-approved test. (Source: Roche Investor Update)
Source: Roche Investor Update - March 11, 2019 Category: Pharmaceuticals Source Type: news

FDA grants Roche ’s Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer
Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Tecentriq ® (atezolizumab) plus chemotherapy (Abraxane® [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in people whose tumours express PD-L1, as determined by an FDA-approved test. (Source: Roche Media News)
Source: Roche Media News - March 11, 2019 Category: Pharmaceuticals Source Type: news

Throat cancer tumours can now be cut out by a robot
The 90minute op is designed to dramatically reduce the need for gruelling radiotherapy and chemotherapy, which can leave patients unable to swallow and dependent on a feeding tube for life. (Source: the Mail online | Health)
Source: the Mail online | Health - March 10, 2019 Category: Consumer Health News Source Type: news

AHN Cancer Institute opens in Butler
Allegheny Health Network on Friday afternoon opened its second of six cancer centers, this one in Butler. The 34,000-square-foot, two-story facility, off Hollywood Road in the Pullman center Business Park, will allow cancer patients to get radiation and chemotherapy as well as other services locally instead of having to drive south to Pittsburgh. About 65 people are employed at the facility, which c ost $21 million to build and will open officially with its first patients Tuesday. "AHN Cancer… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 8, 2019 Category: Biotechnology Authors: Paul J. Gough Source Type: news

AHN Cancer Institute opens in Butler
Allegheny Health Network on Friday afternoon opened its second of six cancer centers, this one in Butler. The 34,000-square-foot, two-story facility, off Hollywood Road in the Pullman center Business Park, will allow cancer patients to get radiation and chemotherapy as well as other services locally instead of having to drive south to Pittsburgh. About 65 people are employed at the facility, which c ost $21 million to build and will open officially with its first patients Tuesday. "AHN Cancer… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 8, 2019 Category: American Health Authors: Paul J. Gough Source Type: news

FDA Approves First Immunotherapy for Breast Cancer FDA Approves First Immunotherapy for Breast Cancer
For use in advanced triple-negative disease, atezolizumab is approved in combination with the chemotherapy nab-paclitaxel. The pairing improved progression-free survival.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 8, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Chemo Is'Invisible Threat' to Cancer Clinic Staff Chemo Is'Invisible Threat' to Cancer Clinic Staff
Because of its toxicity, chemotherapy is an occupational hazard for the staff of cancer clinics, but related safety issues do not seem to be a major clinical concern or a topic of much research.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 8, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Roche gets European approval for Tecentriq combo vs. lung cancer
Roche has received European Commission approval for its Tecentriq drug in combination with Avastin and chemotherapy as an initial treatment for people with a specific type of lung cancer, the Swiss pharma company said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - March 8, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Roche today announced that the European Commission has approved and granted marketing authorisation for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - March 8, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Roche today announced that the European Commission has approved and granted marketing authorisation for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - March 8, 2019 Category: Pharmaceuticals Source Type: news

Alex Trebek Confronting Devastating Stage IV Cancer Diagnosis
BOSTON (CBS) – Paul Mosca knows he has beaten the odds. He was diagnosed four years ago with pancreatic cancer, which has the lowest survival rate among all the major cancers. “It felt like my feet were nailed to the floor I couldn’t move. I thank God every day I’m alive,” Mosca tells WBZ-TV. Fortunately for Paul it was detected early due to MRI screenings that he was already getting for chest pain and underwent surgery. “Here I am four years later with no cancer,” he says. Cancer survivor Paul Mosca (WBZ-TV) Doctors say the outlook is not so optimistic for “Jeopardy!”...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - March 7, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Syndicated Local Watch Listen Alex Trebek Beth Germano Pancreatic Cancer Source Type: news

For Alex Trebek, the Toughest Question: Can He Face Down Pancreatic Cancer?
The iconic talk show host has been handed a frightening diagnosis. Here ’ s what it means. (Source: NYT Health)
Source: NYT Health - March 7, 2019 Category: Consumer Health News Authors: GINA KOLATA Tags: Pancreatic Cancer Pancreas Surgery and Surgeons Chemotherapy Tumors Deaths (Fatalities) Memorial Sloan-Kettering Cancer Center University of Pennsylvania Trebek, Alex Source Type: news

The Slippery Slope: If Facebook bans content that questions vaccine dogma, will it soon ban articles about toxic chemotherapy, fluoride and pesticides, too?
(Natural News) In accordance with the company’s ongoing efforts to censor all truth while promoting only establishment fake news on its platform, social media giant Facebook has decided to launch full-scale war against online free speech about vaccines. Pandering to the demands by California Democrat Adam Schiff, Mark Zuckerberg and his team recently announced that... (Source: NaturalNews.com)
Source: NaturalNews.com - March 7, 2019 Category: Consumer Health News Source Type: news

Pancreatic Cancer: Dr. Mallika Marshall On Alex Trebek ’ s Diagnosis
BOSTON (CBS) — “Jeopardy!” host Alex Trebek announced Wednesday that he is battling stage 4 pancreatic cancer.  A Message from Alex Trebek: pic.twitter.com/LbxcIyeTCF — Jeopardy! (@Jeopardy) March 6, 2019 The 78-year-old Trebek, who has hosted the popular quiz show since 1984, vowed to keep working and said “I plan to beat the low survival rate statistics for this disease.” WBZ-TV’s Dr. Mallika Marshall sat down with David Wade and Lisa Hughes to answer questions about this deadly cancer. What Is The Pancreas? It’s an organ that sits behind the stomach. It produces ho...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - March 6, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Syndicated Local Alex Trebek Dr. Mallika Marshall Pancreatic Cancer Source Type: news

A Man May Be Cleared of HIV for the Second Time in History. Here ’s What That Means
A man in London has become only the second person to achieve remission from HIV infection, researchers from the UK reported Tuesday. The therapy responsible has worked on only one other person who is considered to be “cured” of HIV: Timothy Ray Brown, who still does not show signs of the virus in his body after more than 10 years. Here’s what to know about the landmark case. How did it happen? In a letter published in the journal Nature, researchers led by Ravindra Gupta from the University of Cambridge London and Imperial College London and his colleagues say that they used a treatment similar to the one...
Source: TIME: Health - March 5, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized HIV/AIDS Source Type: news

Targeting Blood-Clotting Pathway Improves Mesothelioma Treatment
A team of researchers at the Cancer and Vascular Biology Research Center in Haifa, Israel, and the Langone Medical Center in New York collaborated on research of a common blood-clotting pathway. Targeting this pathway may offer a unique avenue for improving existing mesothelioma treatments. Researchers said the standard first-line chemotherapy for malignant pleural mesothelioma — a combination of Alimta (pemetrexed) and cisplatin — offers little benefit to most mesothelioma patients. “This treatment regimen confers a median progression-free survival of 5.7 months,” according to the study published ...
Source: Asbestos and Mesothelioma News - March 5, 2019 Category: Environmental Health Authors: Walter Pacheco Source Type: news

Pharma's message: Hey America, eat anything you want, because you'll be rescued by drugs, heart surgery, and chemotherapy
(Natural News) In certain ways, Western medicine is a miracle. If you suffer a compound fracture or some horrendous deep wound, you can be rushed to the hospital in an ambulance and have a surgeon reset your bones and sew you up quick, and maybe even save your life in the process. Or, should you... (Source: NaturalNews.com)
Source: NaturalNews.com - March 5, 2019 Category: Consumer Health News Source Type: news

'Outlier' trust addresses cancer service concerns
A trust has made changes to its lung cancer service after concerns patients were much less likely to access chemotherapy and other anti-cancer therapies than elsewhere in the country. (Source: HSJ)
Source: HSJ - March 5, 2019 Category: UK Health Source Type: news

Washington mom says she's cant vaccinate her five-year-old battling cancer and slams anti-vaxxers
Kai Bonneau, five, of Vancouver, Washington, has been battling acute lymphoblastic leukemia. He can't receive any vaccines until he's done with chemotherapy treatments. (Source: the Mail online | Health)
Source: the Mail online | Health - March 5, 2019 Category: Consumer Health News Source Type: news

Chemotherapy workers face risks, reduced with safe handling
Analysis finds moderate level of evidence that workplace exposure is associated with increased risk of miscarriage and genetic damage (read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - March 4, 2019 Category: Environmental Health Source Type: news

Belgian EPP Study Shows Mesothelioma Surgery Extends Survival
Using proper patient selection, doctors in Leuven, Belgium, are extending mesothelioma survival times significantly with the controversial extrapleural pneumonectomy surgery. Despite a growing reluctance to perform the surgery within the United States and throughout much of Europe, mesothelioma specialists at University Hospitals KU Leuven have continued performing it with great success. Their 2018 single-center study of the extrapleural pneumonectomy (EPP) for pleural mesothelioma produced a 33.2-month median survival and a 24.2 percent five-year survival. “With our dedicated team, a patient can do well with this su...
Source: Asbestos and Mesothelioma News - March 4, 2019 Category: Environmental Health Authors: Walter Pacheco Source Type: news

Genomics could better match treatments to pancreatic cancer patients
(University of Pittsburgh) Pancreatic cancer is a grim diagnosis, but this new study, the largest of its kind, identifies genomic markers that could increase survival by better matching chemotherapy drugs to patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 4, 2019 Category: Cancer & Oncology Source Type: news

Shares of Waltham drugmaker ImmunoGen crater after late-stage trial fail
The future of beleaguered biotech ImmunoGen Inc.'s lead drug candidate is uncertain after the company revealed Friday that the ovarian cancer treatment failed in a late stage trial. In a 366-person Phase 3 trial, ImmunoGen's (Nasdaq: IMGN) ovarian cancer drug was linked to a higher initial response rate compared to chemotherapy, but failed to lead to a longer survival rate without the cancer spreading. The company's shares were down 47 percent in premarket trading as of 8 a. m., implying the stock… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 1, 2019 Category: American Health Authors: Allison DeAngelis Source Type: news

Long-Term Cardiomyopathy Risk Varies by Chemo Agent
FRIDAY, March 1, 2019 -- Long-term cardiomyopathy risk varies by chemotherapy agent for childhood cancer survivors, with a decreased risk for daunorubicin versus doxorubicin, according to a study recently published in JAMA Oncology. Elizabeth A.M.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 1, 2019 Category: Pharmaceuticals Source Type: news

Woman who battled 12 rounds of chemotherapy credits an ice cap for helping her keep her hair
Amanda White, 37, of Didsbury, Manchester, found a lump in her breast in January 2017 while training to trek to Everest Base Camp. She wore a cooling cap before, during and after chemotherapy. (Source: the Mail online | Health)
Source: the Mail online | Health - March 1, 2019 Category: Consumer Health News Source Type: news

Researchers search for solutions to 'invisible threat' that affects cancer care workers
(Michigan Medicine - University of Michigan) A study from the University of Michigan Rogel Cancer Center sought to improve nurses' handling of chemotherapy by delivering an educational intervention with quarterly reminders and tailored messages. But despite the strong study design and quality intervention, it did not increase use of protective gear. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 1, 2019 Category: International Medicine & Public Health Source Type: news

Wake-up call for scientists: A growing number of cancer patients are choosing cannabis oil over chemo, and some researchers have decided to check it out
(Natural News) Despite the grand conspiracy to keep the medicinal benefits of cannabis inaccessible, it’s growing ever more obvious that marijuana prohibition exists solely to benefit the pharmaceutical industry. Cancer patients around the world are beginning to forego chemotherapy, and instead, are turning to cannabis or cannabis oil to treat their cancer. And as the... (Source: NaturalNews.com)
Source: NaturalNews.com - March 1, 2019 Category: Consumer Health News Source Type: news

How Does Bev + Chemo Perform in'Real World' Ovarian Cancer? How Does Bev + Chemo Perform in'Real World' Ovarian Cancer?
Patients in the nonresearch setting receiving bevacizumab with chemotherapy for ovarian cancer have impressive progression-free survival rates, says Maurie Markman.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 28, 2019 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers
Roche today announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta ™ (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment of certain people with HER2-positive early breast cancer (node-positive, or node-negative and ER/PR-negative or with one high-risk feature) in combination with chemotherapy and HER2-positive metast atic breast cancer in combination with paclitaxel or alone in people who have received one or more chemotherapy regimens for metastatic disease. (Source: Roche Investor Update)
Source: Roche Investor Update - February 28, 2019 Category: Pharmaceuticals Source Type: news